Filed Pursuant to Rule
424(b)(3)
Registration No. 333-239851
PROSPECTUS SUPPLEMENT
(To Prospectus Dated July 21, 2020)
PREDICTIVE ONCOLOGY INC.
1,396,826 Shares of Common Stock
This prospectus supplement (“Supplement”) modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) by Predictive Oncology Inc. (the “Company”), dated July 21, 2020, related to the resale from time to time by the selling stockholders named therein of 1,396,826 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) issuable upon the exercise of outstanding warrants at an original exercise price of $1.80 per share expiring on December 26, 2025 ( the “Existing Warrants”). Some of the Existing Warrants have been amended as described below under “Amendments to Existing Warrants.”
The Common Stock is listed on the Nasdaq Capital Market under the symbol “POAI.” On May 18, 2022, the last reported sale price of the Common Stock on the Nasdaq Capital Market was $0.336 per share.
The information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus. This Supplement is not complete without, and may not be delivered or used except in connection with, the Prospectus. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.
We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.
Investing in our securities involves risks. See “Risk Factors” on page 9 of the Prospectus and the risks described in the documents incorporated by reference in the Prospectus, including the risks described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
FORWARD-LOOKING STATEMENTS
You should carefully consider the risk factors set forth in the Prospectus, as well as the other information contained in this Supplement and the Prospectus. This Supplement and the Prospectus contains forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the Prospectus and the reports incorporated by reference therein identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made or included in this Supplement and the Prospectus.
AMENDMENTS TO EXISTING WARRANTS
This Supplement is being filed to disclose the following:
On May 18, 2022, in connection with a securities purchase agreement entered into by the Company with certain institutional and accredited investors, including a holder of the Existing Warrants, the Company filed a prospectus supplement (the “Registered Direct Prospectus Supplement”) and the accompanying base prospectus with the SEC under the Company’s registration statement on Form S-3 (Registration No. 333-254309). Pursuant to the securities purchase agreement and the Registered Direct Prospectus Supplement, the Company offered and sold an aggregate of 8,162,720 shares of its Common Stock, at a purchase price of $0.60 per share (the “Registered Direct Offering”). In connection with the Registered Direct Offering, the Company entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with each of the purchasers in the Registered Direct Offering under which the Company agreed to amend certain outstanding warrants to purchase up to an aggregate of 16,325,435 shares of common stock that were previously issued in 2020 and 2021 to the purchasers, with exercise prices ranging from $1.00 to $2.00 per share, in consideration for their purchase of approximately $4.9 million of Common Stock in the Registered Direct Offering.
Under the Warrant Amendment Agreement, with respect to the Existing Warrants held by the investor in the Registered Direct Offering and covered by the Warrant Amendment Agreement, the Company agreed to (i) lower the exercise price of the Existing Warrants to $0.70 per share, (ii) provide that the Existing Warrants, as amended, will not be exercisable until November 18, 2022 (six months following the closing date of the Registered Direct Offering) and (iii) extend the original expiration date of the Existing Warrants to November 18, 2027 (five and one-half years following the close of the Registered Direct Offering). The amendment became effective on May 18, 2022, when the closing of the Registered Direct Offering occurred and such purchaser satisfied its purchase commitment to the Company.
Existing Warrants to purchase up to an aggregate of 698,413 shares of Common Stock are held by the selling stockholder named in the Prospectus and subject to the Warrant Amendment Agreement. The following selling stockholder named in the Prospectus participated in the Registered Direct Offering and entered into the Warrant Amendment Agreement with respect to the following number of shares being offered pursuant to the Prospectus, as amended by this Supplement, all of which shares are issuable upon exercise of its Existing Warrants as amended: Armistice Capital Master Fund, 698,413 shares. No changes have been made to the other Existing Warrants to purchase up to an aggregate of 698,413 shares of Common Stock, which shares may be resold under the Prospectus, as amended by this Supplement.
The date of this Prospectus Supplement is May 18, 2022.
2